Synthetic and Analytical Methods Targeting Telomerase

靶向端粒酶的合成和分析方法

基本信息

  • 批准号:
    7017738
  • 负责人:
  • 金额:
    $ 18.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-04-01 至 2008-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The major long term objective of this application is to establish a new strategy to inhibit the enzyme telomerase. Telomerase is a promising universal anti-cancer target. Its activity is found in a majority of cancer cells and immortal cell lines, while being absent from a majority of healthy somatic cells. In addition to this correlation there are strong mechanistic reasons why cancer cells require telomerase. The central hypothesis of this project is that molecules which can bind the RNA/DNA duplex formed during telomerase's catalytic cycle will act as inhibitors of the enzyme, and will therefore be potential anti-cancer therapeutics. The postulated mechanism by which these molecules will inhibit the enzyme is either through the prevention of strand dissociation, a key step in telomerase's catalytic cycle, or by the distortion of the duplex substrate, leading to poor catalysis. Our preliminary studies have demonstrated that known RNA/DNA duplex binding molecules are able to inhibit telomerase, and do so in a manner consistent with this inhibition being due to interaction with the RNA/DNA duplex. The specific aims of this work are: 1) Assess known duplex binding molecules such as intercalators for activity as telomerase inhibitors. This assessment will include in-depth kinetic analysis of the mode of inhibition to definitively characterize the mechanism of action of the compounds 2) Use the most successful compounds as the basis of diverse libraries of compounds synthesized using combinatorial chemistry. The purpose of this is to introduce new moieties into the molecule, which will then introduce specific interactions with the unique surrounding telomerase surfaces. 3) Develop high throughput assays, including affinity methods and enzyme assays, which we will use to identify molecules from the combinatorial libraries with the highest affinity for telomerase. These techniques will allow the rapid assessment of large numbers of compounds, allowing a small group of high affinity compounds to be isolated from a large mixture. Combined, these three aims will allow the validation of a new approach for telomerase inhibition and the development of high specificity, high affinity lead inhibitors.
描述(由申请人提供):本申请的主要长期目标是建立一种抑制端粒酶的新策略。端粒酶是一种很有前途的通用抗癌靶点。它的活性在大多数癌细胞和不朽细胞系中发现,而在大多数健康体细胞中不存在。除了这种相关性之外,癌细胞需要端粒酶还有很强的机制原因。该项目的中心假设是,能够结合端粒酶催化循环过程中形成的RNA/DNA双链的分子将作为端粒酶的抑制剂,因此将成为潜在的抗癌疗法。这些分子抑制端粒酶的假设机制要么是通过阻止链解离(端粒酶催化循环的关键步骤),要么是通过双相底物的扭曲,导致催化效果差。我们的初步研究表明,已知的RNA/DNA双链结合分子能够抑制端粒酶,并且这种抑制作用与RNA/DNA双链相互作用的方式一致。这项工作的具体目的是:1)评估已知的双相结合分子,如插入物作为端粒酶抑制剂的活性。该评估将包括对抑制模式的深入动力学分析,以明确表征化合物的作用机制2)使用最成功的化合物作为使用组合化学合成的各种化合物文库的基础。这样做的目的是在分子中引入新的部分,然后引入与周围独特的端粒酶表面的特定相互作用。3)开发高通量分析,包括亲和力方法和酶分析,我们将使用这些方法从组合文库中鉴定对端粒酶具有最高亲和力的分子。这些技术将允许快速评估大量化合物,允许从大量混合物中分离出一小组高亲和力化合物。结合这三个目标,将允许验证端粒酶抑制的新方法和开发高特异性,高亲和力的铅抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SIMON H FRIEDMAN其他文献

SIMON H FRIEDMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SIMON H FRIEDMAN', 18)}}的其他基金

Continuously Variable Protein Delivery Using a Photoactivated Depot
使用光激活库进行连续可变的蛋白质递送
  • 批准号:
    10606514
  • 财政年份:
    2020
  • 资助金额:
    $ 18.43万
  • 项目类别:
Continuously Variable Protein Delivery Using a Photoactivated Depot
使用光激活库进行连续可变的蛋白质递送
  • 批准号:
    10379467
  • 财政年份:
    2020
  • 资助金额:
    $ 18.43万
  • 项目类别:
Continuously Variable Protein Delivery Using a Photoactivated Depot
使用光激活库进行连续可变的蛋白质递送
  • 批准号:
    10197122
  • 财政年份:
    2020
  • 资助金额:
    $ 18.43万
  • 项目类别:
Synthetic and Analytical Methods Targeting Telomerase
靶向端粒酶的合成和分析方法
  • 批准号:
    6874956
  • 财政年份:
    2003
  • 资助金额:
    $ 18.43万
  • 项目类别:
Synthetic and Analytical Methods Targeting Telomerase
靶向端粒酶的合成和分析方法
  • 批准号:
    7211402
  • 财政年份:
    2003
  • 资助金额:
    $ 18.43万
  • 项目类别:
Synthetic and Analytical Methods Targeting Telomerase
靶向端粒酶的合成和分析方法
  • 批准号:
    6729008
  • 财政年份:
    2003
  • 资助金额:
    $ 18.43万
  • 项目类别:
Synthetic and Analytical Methods Targeting Telomerase
靶向端粒酶的合成和分析方法
  • 批准号:
    6574553
  • 财政年份:
    2003
  • 资助金额:
    $ 18.43万
  • 项目类别:
FULLERENE BASED INHIBITORS OF HIV 1 PROTEASE: STRUCTURE BASED DESIGN
基于富勒烯的 HIV 1 蛋白酶抑制剂:基于结构的设计
  • 批准号:
    6456705
  • 财政年份:
    2001
  • 资助金额:
    $ 18.43万
  • 项目类别:
FULLERENE BASED INHIBITORS OF HIV 1 PROTEASE: STRUCTURE BASED DESIGN
基于富勒烯的 HIV 1 蛋白酶抑制剂:基于结构的设计
  • 批准号:
    6347867
  • 财政年份:
    2000
  • 资助金额:
    $ 18.43万
  • 项目类别:
FULLERENE BASED INHIBITORS OF HIV 1 PROTEASE: STRUCTURE BASED DESIGN
基于富勒烯的 HIV 1 蛋白酶抑制剂:基于结构的设计
  • 批准号:
    6220237
  • 财政年份:
    1999
  • 资助金额:
    $ 18.43万
  • 项目类别:

相似海外基金

Role of novel RNA binding protein LARP6 in alcoholic cardiomyopathy
新型RNA结合蛋白LARP6在酒精性心肌病中的作用
  • 批准号:
    10593688
  • 财政年份:
    2023
  • 资助金额:
    $ 18.43万
  • 项目类别:
Targeting of RNA-binding protein FXR1 in HNSCC
HNSCC 中 RNA 结合蛋白 FXR1 的靶向
  • 批准号:
    10571379
  • 财政年份:
    2023
  • 资助金额:
    $ 18.43万
  • 项目类别:
Mechanisms driving Autosomal Dominant Polycystic Kidney Disease: The novel role of the RNA-binding protein ANKHD1.
常染色体显性多囊肾病的驱动机制:RNA 结合蛋白 ANKHD1 的新作用。
  • 批准号:
    MR/T04201X/2
  • 财政年份:
    2023
  • 资助金额:
    $ 18.43万
  • 项目类别:
    Fellowship
Identify the role of RNA-binding protein in activating anti-tumor immunity by directly decaying PD-L1-3'UTR
通过直接降解 PD-L1-3UTR 鉴定 RNA 结合蛋白在激活抗肿瘤免疫中的作用
  • 批准号:
    23KJ1296
  • 财政年份:
    2023
  • 资助金额:
    $ 18.43万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Anti-inflammatory Signaling of RNA-binding Protein, Tristetraprolin, During Myocardial Infarction
RNA 结合蛋白 Tristetraprolin 在心肌梗死期间的抗炎信号传导
  • 批准号:
    10644962
  • 财政年份:
    2023
  • 资助金额:
    $ 18.43万
  • 项目类别:
Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy
tau蛋白病中含有RNA结合蛋白SFPQ的病理应激颗粒的形成和功能
  • 批准号:
    10581946
  • 财政年份:
    2023
  • 资助金额:
    $ 18.43万
  • 项目类别:
ERK-mediated regulation of RNA binding protein condensation during female germ cell development
ERK 介导的雌性生殖细胞发育过程中 RNA 结合蛋白凝聚的调节
  • 批准号:
    10514951
  • 财政年份:
    2022
  • 资助金额:
    $ 18.43万
  • 项目类别:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
  • 批准号:
    10634764
  • 财政年份:
    2022
  • 资助金额:
    $ 18.43万
  • 项目类别:
Post-transcriptional regulation by the YBX3 RNA-binding protein in skeletal muscle
骨骼肌中 YBX3 RNA 结合蛋白的转录后调节
  • 批准号:
    10439013
  • 财政年份:
    2022
  • 资助金额:
    $ 18.43万
  • 项目类别:
Evolution of RNA Binding Protein Regulation of Brain Development
RNA结合蛋白对大脑发育调节的进化
  • 批准号:
    2735241
  • 财政年份:
    2022
  • 资助金额:
    $ 18.43万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了